Scilex Holding (SCLXW) Amortization - Intangibles (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Amortization - Intangibles of $2.1 million in Q1 2026, up 56.82% quarter-over-quarter from $1.3 million in Q4 2025, and up 108.78% on a YoY basis from $1.0 million in Q1 2025.
Scilex Holding (SCLXW) Amortization - Intangibles (2022 - 2026) Analysis & Trends
Scilex Holding's Amortization - Intangibles history runs 5 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 108.78% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $5.4 million (up 36.01% YoY), while the FY2025 annual figure was $4.4 million, up 8.26% from the prior year.
- Amortization - Intangibles was $2.1 million for Q1 2026 at Scilex Holding, up from $1.3 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $2.1 million in Q1 2026 to a low of $935000.0 in Q1 2022.
- Historically, Amortization - Intangibles has averaged $1.1 million across 5 years, with a median of $1.0 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Amortization - Intangibles declined 2.53% in 2023, then jumped 108.78% in 2026.
- A 5-year view of Amortization - Intangibles shows it stood at $1.0 million in 2022, then declined by 0.0% to $1000000.0 in 2023, then gained by 0.1% to $1.0 million in 2024, then surged by 33.27% to $1.3 million in 2025, then surged by 56.82% to $2.1 million in 2026.
- The last three Amortization - Intangibles figures came in at $2.1 million (Q1 2026), $1.3 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.09 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1,000,000.00 |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 935,000.00 |
| Mar 31, 2022 | 935,000.00 |